0001193125-24-160292.txt : 20240613 0001193125-24-160292.hdr.sgml : 20240613 20240613071732 ACCESSION NUMBER: 0001193125-24-160292 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240613 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240613 DATE AS OF CHANGE: 20240613 FILER: COMPANY DATA: COMPANY CONFORMED NAME: REPLIGEN CORP CENTRAL INDEX KEY: 0000730272 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 042729386 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-14656 FILM NUMBER: 241040007 BUSINESS ADDRESS: STREET 1: 41 SEYON STREET STREET 2: BUILDING 1, SUITE 100 CITY: WALTHAM STATE: MA ZIP: 02453 BUSINESS PHONE: 7814499560 MAIL ADDRESS: STREET 1: 41 SEYON STREET STREET 2: BUILDING 1, SUITE 100 CITY: WALTHAM STATE: MA ZIP: 02453 8-K 1 d126737d8k.htm 8-K 8-K
REPLIGEN CORP false 0000730272 0000730272 2024-06-13 2024-06-13

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 13, 2024

 

 

REPLIGEN CORPORATION

(Exact name of registrant as specified in charter)

 

 

 

Delaware   000-14656   04-2729386
(State or Other Jurisdiction
of Incorporation)		   (Commission
File Number)		   (IRS Employer
Identification No.)

41 Seyon Street, Bldg. 1, Suite 100, Waltham, MA 02453

(Address of Principal Executive Offices) (Zip Code)

(781) 250-0111

(Registrant’s telephone number, including area code)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading
Symbol(s)

  

Name of each exchange
on which registered

Common Stock, par value $0.01 per share   RGEN   The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 7.01 Regulation FD Disclosure.

On June 13, 2024, Repligen Corporation (“Repligen”) issued a press release announcing that Tony J. Hunt will transition from his role as Repligen’s Chief Executive Officer to Executive Chair, and that Olivier Loeillot, Repligen’s President and Chief Commercial Officer, has been appointed as his successor, effective September 1, 2024. Repligen also announced that, as part of the transition, Karen A. Dawes, the current Chair of the Repligen board of directors, will assume the role of Lead Independent Director, also effective September 1, 2024.

A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated into this Item 7.01 by reference.

The information in this Item 7.01, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

 

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit
No.		    Description
99.1    Press release issued by Repligen Corporation on June 13, 2024 (furnished herewith).
104    Cover page from this Current Report on Form 8-K, formatted in Inline XBRL

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    REPLIGEN CORPORATION
Dated: June 13, 2024     By:  

/s/ Tony J. Hunt

      Tony J. Hunt
      Chief Executive Officer
 EX-99.1 2 d126737dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

 

   

Repligen Corporation

41 Seyon Street

Building #1, Suite 100

Waltham, Massachusetts 02453

REPLIGEN ANNOUNCES CEO TRANSITION PLAN

Tony J. Hunt to Transition from Chief Executive Officer to Executive Chair, Olivier Loeillot Appointed to Role of President and Chief Executive Officer, Effective September 1, 2024

WALTHAM, Mass., June 13, 2024 — Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that its Board of Directors (“Board”) has approved the planned transition of Tony J. Hunt from Chief Executive Officer (“CEO”) to Executive Chair, effective September 1, 2024. The Company’s Board has appointed Olivier Loeillot to succeed Mr. Hunt in the role of President and CEO, also effective September 1, 2024. At the same time, Mr. Loeillot, who joined the Company in October 2023 as President and Chief Commercial Officer, will join the Repligen Board, while current Board Chair Karen A. Dawes will assume the role of Lead Independent Director.

Mr. Hunt has served as Chief Executive Officer and a member of the Company’s Board of Directors since May 2015, successfully leading the Company to innovation leadership in bioprocessing. Under his direction, the Company has enjoyed consistent above-industry growth through disciplined acquisitions (M&A), internal product development (R&D), commercial execution and operational excellence. During Mr. Hunt’s tenure as CEO, Repligen’s revenue grew from approximately $63 million in 2014 to $639 million in 2023, representing an average annual growth rate of over 30% over the nine-year period.

Karen A. Dawes, current Board Chair at Repligen, stated, “Over the past two years, the Repligen Board has developed a leadership succession plan to provide for the Company’s ongoing success. Elevating Tony Hunt to Executive Chair and promoting Olivier Loeillot to CEO ensures that we will continue to have a clear strategic vision and achieve our long-term goals. Tony has been an outstanding CEO and we thank him for his leadership and continued commitment to the Company. Olivier, given his exceptional experience and the positive impact he has made since joining Repligen, is an ideal successor to Tony. The Board is confident that he will build on our strong foundation and successfully lead Repligen through the next phase of growth.”

Mr. Loeillot currently oversees the Company’s four business units and the global commercial organization. His focus since joining Repligen has been on driving the commercial and corporate key accounts strategy, participating in strategic planning and evaluating potential business development opportunities. A nearly 30-year industry veteran, Mr. Loeillot previously served for a combined 12 years with Cytiva (a Danaher company) and GE Healthcare Life Sciences. In his most recent role at Cytiva, he served as Bioprocess President from 2018 to 2022, overseeing the multi-billion dollar bioprocess portfolio from cell culture media to purification resins and including process equipment, single-use technologies and enterprise solutions. Prior to Cytiva, he worked for a combined 12 years with Lonza, advancing to Vice President Sales, Lonza Custom Manufacturing.

 

1

Olivier Loeillot, President and Chief Commercial Officer at Repligen, said, “I am delighted and honored to take on the leadership role of President and CEO. Repligen is highly regarded in the bioprocessing industry and has achieved remarkable success under Tony’s leadership. Since joining this results-focused team, I have been very impressed with the company’s culture of innovation, commitment to its employees and customers, and its drive for excellence. I look forward to working with Tony and the Board to lead this high-performing organization to an even more successful future.”

Tony J. Hunt, current CEO at Repligen, said, “It has been my privilege to lead Repligen for over nine years and execute on the vision we set to bring disruptive, high value bioprocessing technologies to market. Having known and respected Olivier for many years – and now having worked directly with him over the past months – I share the Board’s confidence that Olivier is an excellent choice for the CEO role and for the future of Repligen. As Executive Chair, I look forward to working with Olivier and focusing on corporate strategy, new product and business opportunities.”

About Repligen Corporation

Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are “inspiring advances in bioprocessing” for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, France, Germany, Ireland, the Netherlands and Sweden. For more information about the our company see our website at www.repligen.com, and follow us on LinkedIn.

This press release may contain forward-looking statements within the meaning of the federal securities laws. Investors are cautioned that statements in this press release which are not strictly historical statements including, without limitation, statements identified by words like “believe,” “expect,” “may,” “will,” “should,” “seek,” or “could” and similar expressions, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including risks discussed from time to time in our filings with the Securities and Exchange Commission. We expressly disclaim any responsibility to update any forward-looking statements, except as required by law.

 

2

Repligen Contact:

Sondra S. Newman

Global Head of Investor Relations

(781) 419-1881

investors@repligen.com

# # #

 

3

EX-101.SCH 3 rgen-20240613.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 rgen-20240613_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Entity Registrant Name Entity Registrant Name Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, Address Line Three Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 5 rgen-20240613_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g126737g0613030111046.jpg GRAPHIC begin 644 g126737g0613030111046.jpg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end XML 8 R1.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Document and Entity Information
Jun. 13, 2024
Cover [Abstract]  
Entity Registrant Name REPLIGEN CORP
Amendment Flag false
Entity Central Index Key 0000730272
Document Type 8-K
Document Period End Date Jun. 13, 2024
Entity Incorporation State Country Code DE
Entity File Number 000-14656
Entity Tax Identification Number 04-2729386
Entity Address, Address Line One 41 Seyon Street
Entity Address, Address Line Two Bldg. 1
Entity Address, Address Line Three Suite 100
Entity Address, City or Town Waltham
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02453
City Area Code (781)
Local Phone Number 250-0111
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, par value $0.01 per share
Trading Symbol RGEN
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.1.u2 html 1 24 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.repligencorp.com//20240613/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityRegistrantName - d126737d8k.htm 7 d126737d8k.htm rgen-20240613.xsd rgen-20240613_lab.xml rgen-20240613_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "d126737d8k.htm": { "nsprefix": "rgen", "nsuri": "http://www.repligencorp.com/20240613", "dts": { "inline": { "local": [ "d126737d8k.htm" ] }, "schema": { "local": [ "rgen-20240613.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd" ] }, "labelLink": { "local": [ "rgen-20240613_lab.xml" ] }, "presentationLink": { "local": [ "rgen-20240613_pre.xml" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 3, "http://xbrl.sec.gov/dei/2023": 3 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 25, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://www.repligencorp.com//20240613/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "duration_2024-06-13_to_2024-06-13", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d126737d8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "duration_2024-06-13_to_2024-06-13", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d126737d8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.repligencorp.com//20240613/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.repligencorp.com//20240613/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.repligencorp.com//20240613/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.repligencorp.com//20240613/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.repligencorp.com//20240613/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.repligencorp.com//20240613/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://www.repligencorp.com//20240613/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "terseLabel": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.repligencorp.com//20240613/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.repligencorp.com//20240613/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.repligencorp.com//20240613/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.repligencorp.com//20240613/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.repligencorp.com//20240613/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.repligencorp.com//20240613/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.repligencorp.com//20240613/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.repligencorp.com//20240613/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.repligencorp.com//20240613/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.repligencorp.com//20240613/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.repligencorp.com//20240613/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.repligencorp.com//20240613/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.repligencorp.com//20240613/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security 12b Title", "terseLabel": "Security 12b Title", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.repligencorp.com//20240613/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.repligencorp.com//20240613/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "terseLabel": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.repligencorp.com//20240613/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.repligencorp.com//20240613/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "terseLabel": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 17 0001193125-24-160292-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-24-160292-xbrl.zip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end XML 19 d126737d8k_htm.xml IDEA: XBRL DOCUMENT 0000730272 2024-06-13 2024-06-13 REPLIGEN CORP false 0000730272 8-K 2024-06-13 DE 000-14656 04-2729386 41 Seyon Street Bldg. 1 Suite 100 Waltham MA 02453 (781) 250-0111 false false false false Common Stock, par value $0.01 per share RGEN NASDAQ false